|The ATG9B atg9b (Catalog #MBS9220076) is a Blocking Peptide and is intended for research purposes only. The product is available for immediate purchase.
The ATG9B atg9b product has the following accession number(s) (GI #74708555) (NCBI Accession #Q674R7.1) (Uniprot Accession #Q674R7). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Involved in autophagy and cytoplasm to vacuole transport (Cvt) vesicle formation. Plays a key role in the organization of the preautophagosomal structure/phagophore assembly site (PAS), the nucleating site for formation of the sequestering vesicle (By similarity).
Cellular Location: Cytoplasmic vesicle, autophagosome membrane; Multi-pass membrane protein. Note: Under amino acid starvation or rapamycin treatment, redistributes from a juxtanuclear clustered pool to a dispersed peripheral cytosolic pool. The starvation- induced redistribution depends on ULK1 and ATG13. Tissue Location: Highly expressed in placenta (trophoblast cells) and pituitary gland. Not expressed in vascular endothelial. The following patways have been known to be associated with this gene. Embryonic Tissue, Lung, Lymph, Muscle, Placenta, Stomach tissues are correlated with this protein. Breast Neoplasms, Carcinoma, Hypertension, Immune System Diseases, Intestinal Neoplasms, Lung Diseases, Necrosis are some of the diseases may be linked to ATG9B Antibody (C-term) Blocking peptide.